BP
AMGN icon

Ballentine Partners’s Amgen AMGN Stock Holding History

Ballentine Partners’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71M Buy
10,242
+159
+2% +$54.4K 0.05% 137
2026
Q1 		$3.55M Buy
10,083
+182
+2% +$64.9K 0.05% 128
2025
Q4 		$3.24M Buy
9,901
+278
+3% +$88.2K 0.05% 133
2025
Q3 		$2.72M Sell
9,623
-1,979
-17% -$574K 0.04% 157
2025
Q2 		$3.24M Sell
11,602
-2,447
-17% -$693K 0.05% 130
2025
Q1 		$4.38M Sell
14,049
-48
-0.3% -$14.2K 0.08% 95
2024
Q4 		$3.67M Buy
14,097
+202
+1% +$59.9K 0.06% 107
2024
Q3 		$4.48M Buy
13,895
+2,235
+19% +$731K 0.08% 96
2024
Q2 		$3.64M Buy
11,660
+345
+3% +$101K 0.07% 103
2024
Q1 		$3.22M Buy
11,315
+281
+3% +$82.2K 0.06% 106
2023
Q4 		$3.18M Buy
11,034
+1,225
+12% +$334K 0.06% 106
2023
Q3 		$2.64M Buy
9,809
+2,440
+33% +$609K 0.06% 98
2023
Q2 		$1.64M Sell
7,369
-4,301
-37% -$998K 0.04% 138
2023
Q1 		$2.82M Buy
11,670
+3,226
+38% +$792K 0.07% 101
2022
Q4 		$2.22M Buy
8,444
+384
+5% +$103K 0.07% 106
2022
Q3 		$1.82M Buy
8,060
+631
+8% +$153K 0.06% 106
2022
Q2 		$1.81M Buy
7,429
+22
+0.3% +$5.39K 0.06% 106
2022
Q1 		$1.79M Buy
7,407
+922
+14% +$212K 0.06% 116
2021
Q4 		$1.46M Sell
6,485
-215
-3% -$45.4K 0.04% 140
2021
Q3 		$1.43M Sell
6,700
-110
-2% -$25.3K 0.05% 128
2021
Q2 		$1.66M Buy
6,810
+1,150
+20% +$283K 0.06% 109
2021
Q1 		$1.41M Buy
5,660
+101
+2% +$24.1K 0.05% 115
2020
Q4 		$1.28M Sell
5,559
-1,014
-15% -$234K 0.05% 121
2020
Q3 		$1.67M Buy
6,573
+737
+13% +$183K 0.07% 95
2020
Q2 		$1.38M Buy
5,836
+335
+6% +$76.4K 0.07% 103
2020
Q1 		$1.11M Buy
5,501
+4
+0.1% +$874 0.06% 114
2019
Q4 		$1.32M Buy
5,497
+31
+0.6% +$6.83K 0.06% 127
2019
Q3 		$1.06M Buy
5,466
+130
+2% +$25K 0.05% 142
2019
Q2 		$982K Buy
5,336
+522
+11% +$93.5K 0.05% 150
2019
Q1 		$915K Sell
4,814
-69
-1% -$13.2K 0.05% 139
2018
Q4 		$951K Buy
4,883
+1,481
+44% +$289K 0.05% 121
2018
Q3 		$705K Sell
3,402
-133
-4% -$26.2K 0.04% 164
2018
Q2 		$651K Buy
3,535
+183
+5% +$32.4K 0.04% 159
2018
Q1 		$571K Buy
3,352
+185
+6% +$34K 0.03% 165
2017
Q4 		$551K Sell
3,167
-77
-2% -$13.6K 0.03% 174
2017
Q3 		$604K Sell
3,244
-197
-6% -$34.9K 0.03% 169
2017
Q2 		$620K Buy
3,441
+9
+0.3% +$1.46K 0.05% 169
2017
Q1 		$565K Buy
3,432
+58
+2% +$9.64K 0.04% 113
2016
Q4 		$495K Buy
3,374
+151
+5% +$22.7K 0.04% 114
2016
Q3 		$538K Sell
3,223
-25
-0.8% -$4.23K 0.04% 93
2016
Q2 		$494K Buy
3,248
+34
+1% +$5.29K 0.04% 108
2016
Q1 		$482K Buy
3,214
+55
+2% +$8.17K 0.04% 110
2015
Q4 		$513K Buy
3,159
+265
+9% +$41.7K 0.05% 99
2015
Q3 		$401K Buy
2,894
+153
+6% +$24.1K 0.04% 104
2015
Q2 		$421K Sell
2,741
-10
-0.4% -$1.6K 0.04% 104
2015
Q1 		$440K Sell
2,751
-116
-4% -$18.3K 0.04% 100
2014
Q4 		$456K Buy
2,867
+23
+0.8% +$3.58K 0.05% 93
2014
Q3 		$400K Sell
2,844
-68
-2% -$8.88K 0.05% 95
2014
Q2 		$344K Sell
2,912
-216
-7% -$25K 0.04% 104
2014
Q1 		$385K Buy
3,128
+127
+4% +$15.4K 0.05% 96
2013
Q4 		$343K Buy
3,001
+3
+0.1% +$341 0.04% 109
2013
Q3 		$336K Buy
2,998
+879
+41% +$95.3K 0.04% 104
2013
Q2 		$209K Buy
+2,119
New +$220K 0.03% 117

Other funds holding AMGN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SP
Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Ballentine Partners's AMGN Position: Q2 2026 in Review

Ballentine Partners increased its Amgen (AMGN) stake by 1.6% in Q2 2026, buying an estimated $54.4K and bringing the position to 10,242 shares worth $3.71M. The position accounts for 0.05% of the portfolio, ranked #137.

Ballentine Partners first reported a position in AMGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.48M in Q3 2024. 577 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Ballentine Partners held 10,242 shares of Amgen worth $3.71M as of Q2 2026.
  • Ballentine Partners bought 159 Amgen shares in Q2 2026, an estimated $54.4K.
  • Amgen made up 0.05% of Ballentine Partners's portfolio in Q2 2026, its #137 holding.
  • Ballentine Partners first reported a position in Amgen in Q2 2013 and has held it in 53 quarters since.
  • Ballentine Partners's Amgen position peaked at $4.48M in Q3 2024.
  • 577 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.